Skip to content

Effects of Oxycodone on postoperative analgesia and Immune Fuction in Patients undergong Breast Cancer Surgerygeory

Effects of Oxycodone on postoperative analgesia and Immune Fuction in Patients undergong Breast Cancer Surgerygeory

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109589
Enrollment
Unknown
Registered
2025-09-22
Start date
2025-03-05
Completion date
Unknown
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Trial Group:Following tracheal extubation, intravenous patient-controlled analgesia (PCA) with oliceridine fumarate was initiated for postoperative pain management after PCI. The PCA solution containe
Control Group:Following tracheal extubation, intravenous patient-controlled analgesia (PCA) with sufentanil was initiated for postoperative pain management after PCI. The PCA solution contained 2 µg/k

Sponsors

Shenzhen Nanshan District People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. 18 years 2 hours; 3. BI-RADS category 4; 4. Voluntary participation with signed informed consent; 5. ASA classification I–II;

Exclusion criteria

Exclusion criteria: 1. History of solid organ or bone marrow transplantation; 2. Diseases that may affect immune-related indicators, such as autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus) or malignant hematologic tumors (e.g., leukemia, lymphoma); 3. History of radiotherapy or chemotherapy; 4. Intraoperative blood transfusion; 5. Acute myocardial infarction or severe heart failure (NYHA Class IV); 6. Severe chronic liver disease (Child-Pugh Class C); 7. Chronic kidney disease; 8. Pregnancy or lactation; 9. Acute brain injury (traumatic brain injury, subarachnoid hemorrhage, acute ischemic stroke, acute intracranial hemorrhage, acute intracranial infection); 10. Deafness, aphasia, psychiatric disorders, or severe cognitive impairment; 11. Delayed awakening; failure to extubate within 24 hours postoperatively; direct admission to ICU postoperatively; 12. Intraoperative pathology confirming a benign tumor.

Design outcomes

Primary

MeasureTime frame
The ratio of lymphocyte subsets CD4+ and CD8+ cells in the patient's blood 24 hours after surgery.;

Secondary

MeasureTime frame
Cytokines (IL-10, IL-1a, and IL-6) in the patient's blood.;VAS scores during rest and exercise;Adverse reactions;Patient satisfaction scores;

Countries

China

Contacts

Public ContactWei Hong

Nanshan People's Hospital, Shenzhen

weihong269@163.com+86 137 2875 8271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026